TOP TEN perturbations for 39754_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39754_at
Selected probe(set): 201125_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39754_at (201125_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
PMA study 2 (shRNA contr.) / mock treated / transduced MONO-MAC-6 cell sample
Relative Expression (log2-ratio):5.1878223Number of Samples:3 / 2
Experimental | PMA study 2 (shRNA contr.) |
MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then treated with 10 ng/ml phorbol 12-myristate 13-acetate (PMA). ATC code:--- | |
Control | mock treated / transduced MONO-MAC-6 cell sample |
MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then mock treated. |
PMA study 2 / mock treated MONO-MAC-6 cell sample
Relative Expression (log2-ratio):5.037631Number of Samples:3 / 2
Experimental | PMA study 2 |
MONO-MAC-6 (MM6) cells were treated with 10 ng/ml phorbol 12-myristate 13-acetate (PMA). ATC code:--- | |
Control | mock treated MONO-MAC-6 cell sample |
MONO-MAC-6 (MM6) cells mock treated. |
PMA study 2 (shRNA cycT1) / cycT1 depletion study 2 (shRNA)
Relative Expression (log2-ratio):4.5536013Number of Samples:3 / 2
Experimental | PMA study 2 (shRNA cycT1) |
MONO-MAC-6 (MM6) cells were transduced with shRNA against cyclin T1 and then treated with 10ng/ml phorbol 12-myristate 13-acetate (PMA). ATC code:--- | |
Control | cycT1 depletion study 2 (shRNA) |
MONO-MAC-6 (MM6) cells were transduced with shRNA against cyclin T1 and then mock treated. |
Langerhans cell histiocytosis study 1 / normal plasmocytoid dendritic cell sample
Relative Expression (log2-ratio):4.550576Number of Samples:7 / 3
Experimental | Langerhans cell histiocytosis study 1 |
Langerhans cell histiocytes (LCH) were isolated from LCH lesions of patients undergoing surgery. All patients had single system disease, five patients had bone lesion, one had skin lesion and one had mucosal manifestation. Langerhans cells histiocytes were purified by FACS as CD1a+ / CD270 + population with > 95% purity. | |
Control | normal plasmocytoid dendritic cell sample |
Normal plasmocytoid dendritic cells were isolated from peripheral blood of healthy adult donors. Plasmocytoid dendritic cells were defined as HLA-DR+ / CD45RAhi / CD11c- / BDCA2+ population. |
stem cell differentiation study 59 (iDRG; 9d) / normal embryonic stem cell sample (WA09)
Relative Expression (log2-ratio):-3.8484554Number of Samples:4 / 4
Experimental | stem cell differentiation study 59 (iDRG; 9d) |
Immature dorsal root ganglia neurons (iDRGs) obtained by differentiation of WA09 embryonic stem cells. WA09 cells were differentiated for 8 days and subsequently cryopreserved. After thawing, cells were further differentiated for 1 day. Further details are described in the paper. | |
Control | normal embryonic stem cell sample (WA09) |
Undifferentiated WA09 embryonic stem cell samples. |
LPS study 4 (shRNA contr.) / mock treated / transduced MONO-MAC-6 cell sample
Relative Expression (log2-ratio):3.5550737Number of Samples:2 / 2
Experimental | LPS study 4 (shRNA contr.) |
MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:--- | |
Control | mock treated / transduced MONO-MAC-6 cell sample |
MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then mock treated. |
CNS cancer study 1 (PDX; glioblastoma, NOS; primary) / CNS cancer study 1 (PDX; ependymoma, NOS; primary)
Relative Expression (log2-ratio):-3.2448492Number of Samples:3 / 2
Experimental | CNS cancer study 1 (PDX; glioblastoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary glioblastoma, NOS of the central nervous system (subcutaneously implanted). | |
Control | CNS cancer study 1 (PDX; ependymoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary ependymoma, NOS of the central nervous system (subcutaneously implanted). |
breast cancer study 24 / breast cancer study 22
Relative Expression (log2-ratio):3.1335258Number of Samples:10 / 10
Experimental | breast cancer study 24 |
Freshly purified CD4+ tumor-infiltrating T cells derived from female primary invasive breast ductal carcinoma. For individual patient characteristics see detailed sample information. The initial tissue dissociation was performed mechanically, without enzymatic digestion. | |
Control | breast cancer study 22 |
Freshly purified CD4+ T cells from peripheral blood of female donors with primary invasive breast ductal carcinoma. For individual patient characteristics see detailed sample information. |
OPM-1 / MM1.S
Relative Expression (log2-ratio):-3.077036Number of Samples:4 / 4
Experimental | OPM-1 |
Human primary cancer cell line derived from the peripheral blood of a patient with multiple myeloma. Dexamethasone-resistant. Synonyms:OPM1 Cellosaurus code: | |
Control | MM1.S |
Human primary cancer cell line derived from the peripheral blood of a patient with multiple myeloma. Dexamethasone-sensitive. Parental cell line:: MM.1 Synonyms:MM.1S; MM1-S; MM-1S; MM1S Cellosaurus code: |
LPS study 4 (shRNA cycT1) / cycT1 depletion study 2 (shRNA)
Relative Expression (log2-ratio):3.0655403Number of Samples:2 / 2
Experimental | LPS study 4 (shRNA cycT1) |
MONO-MAC-6 (MM6) cells were transduced with shRNA against cyclin T1 and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:--- | |
Control | cycT1 depletion study 2 (shRNA) |
MONO-MAC-6 (MM6) cells were transduced with shRNA against cyclin T1 and then mock treated. |